Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation

Authors:

Abstract
Aim:  Partial splenic embolization (PSE) is a non‐surgical procedure developed to treat hypersplenism. The purpose of this study is to evaluate therapeutic benefits of PSE with follow‐up radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC) patients with thrombocytopenia.Methods:  Between September 1999 and January 2007, a total of 20 patients with HCC who had a few lesions, each 3 cm or less in diameter, and liver function of Child‐Pugh class A or B were enrolled into our study. The patients were diagnosed with marked thrombocytopenia (3/mm3), or mild thrombocytopenia (3/mm3) with decreased prothrombin activity. They were treated once or twice with PSE. RFA was given as a follow‐up treatment 2 weeks after final PSE. The primary endpoint was a platelet‐count increase and improvement of prothrombin activity, and the secondary endpoint was the initiation of RFA.Results:  PSE was performed successfully in 19 patients (95%). Two weeks after final PSE, platelet counts increased significantly (38 ± 14 × 103/mm3 vs. 97 ± 43 × 103/mm3; P < 0.0001), and prothrombin activity improved significantly (59.3 ± 19.8% vs. 65.2 ± 17.9%; P < 0.0001). No patients had major complications during the PSE procedure. The secondary endpoint was achieved in 18 of 19 patients (94.7%). The mean overall survival was 2257 days (95% confidence interval; range, 1659−2855 days). The Kaplan‐Meier cumulative survival rate was estimated to be 61.9% at 5 years.Conclusions:  PSE is a safe and effective treatment for thrombocytopenia and has adjuvant therapeutic benefits for the therapy of HCC.

This publication has 30 references indexed in Scilit: